EditorialNatural History of NAFLD: Remarkably Benign in the Absence of Cirrhosis
References (23)
- et al.
The prevalence and etiology of elevated aminotransferase levels in the United States
Am J Gastroenterol
(2003) - et al.
The spectrum expandedcryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease
J Hepatol
(2004) - et al.
The natural history of non alcoholic fatty livera follow up study
Hepatology
(1995) - et al.
Non alcoholic fatty liver diseasea spectrum of clinical and pathological severity
Gastroenterology
(1999) - et al.
The natural history of non alcoholic fatty liver diseasea clinical histopathological study
Am J Gastroenterol
(2003) - et al.
The histological course of non alcoholic fatty liver diseasea longitudinal study of 103 patients with sequential liver biopsies
J Hepatol
(2005) - et al.
Pathologic features associated with fibrosis in non alcoholic fatty liver disease
Hum Pathol
(2004) - et al.
Survival, liver failure and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis
Hepatology
(2002) - et al.
Long-term outcomes of cirrhosis in non alcoholic steatohepatitis compared with hepatitis C
Hepatology
(2003) - et al.
Expanding the natural history of non alcoholic steatohepatitisfrom cryptogenic cirrhosis to hepatocellular carcinoma
Gastroenterology
(2002)
The natural history of nonalcoholic fatty liver diseasea population-based cohort study
Gastroenterology
Cited by (136)
Breakthroughs in therapies for NASH and remaining challenges
2022, Journal of HepatologyCitation Excerpt :Recognising the mortality and morbidity burden associated with NASH has been key in acknowledging the major unmet clinical need it presents, especially regarding patient identification and management. The early view of NASH as an “incidentaloma” no longer stands.6–8 Particularly worrisome are reports that the increasing presence of non-alcoholic fatty liver disease (NAFLD) in adolescence precipitates the occurrence of end-stage liver disease much earlier in adulthood than classical descriptions of the disease have suggested.9,10
PAR2 promotes high-fat diet-induced hepatic steatosis by inhibiting AMPK-mediated autophagy
2021, Journal of Nutritional BiochemistryCitation Excerpt :The number of patients with NAFLD is increasing worldwide, and NAFLD can develop into non-alcoholic steatohepatitis, cirrhosis, and hepatic cancer. Therefore, treatment at the NAFLD stage is highly important [13–15]. As the main characteristic of NAFLD development is the accumulation of triglyceride (TG), manipulating the synthesis and degradation of TG is important in the treatment of NAFLD [16–18].
Revealing the role of peroxisome proliferator-activated receptor β/δ in nonalcoholic fatty liver disease
2021, Metabolism: Clinical and ExperimentalNonalcoholic fatty liver disease and use of folate
2019, Molecular Nutrition: VitaminsFatty liver and FGF21 physiology
2017, Experimental Cell ResearchCitation Excerpt :10–20% of individuals with NAFL progress to nonalcoholic steatohepatitis (NASH) which is characterized by hepatocyte lipoapoptosis, inflammation and fibrosis. While fatty liver has a relatively benign prognosis [4], NASH poses a high risk for further progression to cirrhosis and hepatocellular carcinoma (HCC). As a result of the increasing prevalence of obesity, NAFLD is now the most common cause of chronic liver disease in developed as well as developing countries.
NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?
2020, Journal of Clinical and Experimental Hepatology